As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Pernix Therapeutics

  • Tuesday's Range: $0.90-$1.12
  • 52-Week Range: $0.88-$11.02
  • Tuesday's Volume: 3.43 million
  • Three-Month Average Volume: 822,582

Pernix Therapeutics(PTX) - Get Report , a specialty pharmaceutical company, develops, manufactures, markets and sells pharmaceutical products. This stock traded up 19.4% to $1.10 in Tuesday's trading session.

From a technical perspective, Pernix Therapeutics exploded sharply higher on Tuesday right off its new 52-week low of 88 cents per share with monster upside volume flows. This rip to the upside on Tuesday is coming off extremely oversold levels, since the current relative strength index reading for this stock is 28.9. Oversold can always get more oversold, but it's also an area from which a stock can make a powerful bounce higher.

This high-volume rip higher on Tuesday is now quickly pushing shares of Pernix Therapeutics within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to clear Tuesday's intraday high of $1.12 a share and then once it clears more key resistance levels at $1.20 to $1.25 a share with high volume.

Traders should now look for long-biased trades in Pernix Therapeutics as long as it's trending above $1 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 822,582 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.50 to $1.70, or even its 20-day moving average of $1.80 a share.

Amicus Therapeutics

  • Tuesday's Range: $7.75-$8.33
  • 52-Week Range: $4.99-$18.83
  • Tuesday's Volume: 2.84 million
  • Three-Month Average Volume: 2.40 million

Amicus Therapeutics(FOLD) - Get Report , a biopharmaceutical company, focuses on the discovery, development and commercialization of medicines for various rare and orphan diseases. This stock traded up 7.3% to $8.30 in Tuesday's trading session.

From a technical perspective, Amicus Therapeutics ripped sharply higher on Tuesday right above its 20-day moving average of $7.40 a share with above-average volume. This high-volume rip to the upside is now quickly pushing shares of Amicus Therapeutics within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $8.39 to $8.60 a share with high volume.

Traders should now look for long-biased trades in Amicus Therapeutics as long as it's trending above its 20-day moving average of $7.40 a share or above its 50-day moving average of $6.83 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 2.40 million shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10 to $10.50, or even its 200-day moving average of $10.98 a share.

Rockwell Medical

  • Tuesday's Range: $6.22-$6.80
  • 52-Week Range: $5.47-$18.90
  • Tuesday's Volume: 719,000
  • Three-Month Average Volume: 646,874

Rockwell Medical(RMTI) - Get Report  operates as an integrated biopharmaceutical company in the U.S. and internationally. This stock traded up 6.3% to $6.70 in Tuesday's trading session.

From a technical perspective, Rockwell Medical spiked sharply higher on Tuesday right above some near-term support at $6 a share with above-average volume. This high-volume spike to the upside is now quickly pushing shares of Rockwell Medical within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some key near-term overhead resistance levels at its 20-day moving average of $6.88 a share and then above its 50-day moving average of $7.02 a share with high volume.

Traders should now look for long-biased trades in Rockwell Medical as long as it's trending above some near-term support around $6 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 646,874 shares. If that breakout fires off soon, then this stock will set up to re-fill some of its previous gap-down-day zone that started near $10.50 a share.

Momenta Pharmaceuticals

  • Tuesday's Range: $8.78-$9.38
  • 52-Week Range: $7.86-$25.56
  • Tuesday's Volume: 681,000
  • Three-Month Average Volume: 765,513

Momenta Pharmaceuticals(MNTA) - Get Report , a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune diseases. This stock traded up 6.7% to $9.37 in Tuesday's trading session.

From a technical perspective, Momenta Pharmaceuticals ripped sharply higher on Tuesday right off its 20-day moving average of $8.68 a share with decent upside volume flows. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $8.02 to $7.86 a share. Following that potential bottom, shares of Momenta Pharmaceuticals have now started to uptrend back above its 20-day and it has broken out above some near-term overhead resistance levels at $9.02 to $9.29 a share.

This high-volume spike on Tuesday is now quickly pushing this stock within range of triggering another big breakout trade. That trade will trigger if this stock manages to clear some near-term overhead resistance levels at Tuesday's intraday high of $9.38 a share and then above $9.50 a share with high volume.

Traders should now look for long-biased trades in Momenta Pharmaceuticals as long as it's trending above some near-term support at $9 a share or above its 20-day moving average of $8.68 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 765,513 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10 to $10.50, or even its 50-day moving average of $10.67 to $11 a share.

BioDelivery Sciences

  • Tuesday's Range: $2.70-$2.92
  • 52-Week Range: $2.53-$14.88
  • Tuesday's Volume: 1.20 million
  • Three-Month Average Volume: 1.12 million

BioDelivery Sciences(BDSI) - Get Report , a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. This stock closed up 3.9% to $2.89 in Tuesday's trading session.

From a technical perspective, BioDelivery Sciences spiked notably higher on Tuesday right above its new 52-week low of $2.53 a share with above-average volume. This stock has been downtrending badly over the last six months, with shares collapsing off its high of over $7 a share to that new 52-week low of $2.53 a share. During that downtrend, this stock has been making mostly lower highs and lower lows, which is bearish technical price action.

That said, shares of BioDelivery Sciences are now starting to trend higher with volume and are quickly moving within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $3 to $3.10 a share with high volume.

Traders should now look for long-biased trades in BioDelivery Sciences as long as it's trending above Tuesday's intraday low of $2.70 a share or above its new 52-week low of $2.53 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.12 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $3.30 to its 20-day moving average of $3.49, or even its 50-day moving average of $3.69 a share.

Celldex Therapeutics

  • Tuesday's Range: $3.58-$3.99
  • 52-Week Range: $2.69-$30.28
  • Tuesday's Volume: 4.94 million
  • Three-Month Average Volume: 3.86 million

Celldex Therapeutics(CLDX) - Get Report , a biopharmaceutical company, develops, manufactures and commercializes novel therapeutics for human health care in the U.S. This stock traded up 7.7% to $3.89 in Tuesday's trading session.

From a technical perspective, Celldex Therapeutics ripped sharply higher on Tuesday and broke out above some near-term overhead resistance at $3.74 a share with strong upside volume flows. This high-volume spike to the upside is now quickly pushing shares of Celldex Therapeutics within range of triggering a much bigger breakout trade. That trade will hit if this stock manages to take out some key near-term overhead resistance levels at $4.08 to its gap-down-day high from earlier this month at $4.33 a share with high volume.

Traders should now look for long-biased trades in Celldex Therapeutics as long as it's trending above Tuesday's intraday low of $3.58 a share or above more support at $3.45 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.86 million shares. If that breakout hits soon, then this stock will set up to re-fill some of its previous gap-down-day zone that started near $8 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.